Endo International PLC (Nasdaq:ENDP)
June 14th, 2019
Amidst falling markets Endo International PLC finished Friday’s trading session down 9.40%, a ($0.42) decrease to close on $4.05. As well as the drop in value, Endo International PLC hit a new 52 week low of $4.02. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the recommended threshold of 1.8%, and calculated to be -0.69.
ENDP was outperformed by the rest of the Healthcare sector which went down just -0.29%.
The market sectors were mixed Friday with a majority of the sectors trending up. Utilities saw the biggest increase of the day (0.99%), while the Information Technology sector saw the biggest drop (-0.83%). Information Technology has seen the biggest year-to-date gain of 23.33%.
Utilities saw the biggest turn-around compared to its 5-day performance (-0.59%), as it went up by 0.99%. Information Technology and Energy both saw turn-arounds from their five day positive performances with Information Technology dropping -0.83%.
- Utilities, up 0.99%.
- Communication Services, up 0.39%.
- Real Estate, up 0.33%.
- Financials, up 0.26%.
- Consumer Discretionary, up 0.24%.
- Consumer Staples, up 0.03%.
- Healthcare, down -0.29%.
- Industrials, down -0.39%.
- Materials, down -0.47%.
- Energy, down -0.74%.
- Information Technology, down -0.83%.
Endo International PLC Info
Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded – Specialty & Established Pharmaceuticals segment provides branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain, and orthopedics. This segment offers XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL Nasal Spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN Gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; FORTESTA Gel for men suffering from hypogonadism; EDEX to treat erectile dysfunction; and TESTIM for TRT in conditions associated with a deficiency or absence of endogenous testosterone. The company’s U.S. Branded – Sterile Injectables segment offers branded sterile injectable products, such as VASOSTRICT, ADRENALIN, and APLISOL; and generic sterile injectable products. Its U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and cardiovascular disease markets. The company’s International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women’s health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. The company was founded in 1920 and is headquartered in Dublin, Ireland.
All amounts in USD unless otherwise indicated
(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Endo International PLC’s score is -0.69) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.